MSK Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD | Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD | ||
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] | * [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] | ||
Latest revision as of 16:43, 21 December 2023
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Profile Documents
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile